Vážený uživateli, je nám líto, ale Váš prohlížeč nepodporuje plné zobrazení webu. Doporučujeme Vám přejít na jeho aktuálnější verzi (MS Edge) nebo na některý z nejčastějších prohlížečů (Chrome, Firefox, Safari).
Naše společnostiAktuálněInsights

O skupině PPF

O násLidé a statutární orgányFinanční výsledky a výkazyZprávy a dokumenty

Společenská odpovědnost

Společenská odpovědnostUdržitelnost
Pro médiaKontaktyKariéra
en

Novinky do e-mailu

Nechte si zasílat nejnovější tiskové zprávy, rozhovory, podcasty a insighty

Odebírat novinky

Sledujte nás

Pro média

  • Tiskové zprávy
  • Rozhovory a podcasty
  • Odebírat novinky
  • Ke stažení
  • Kontakt pro média

Může se hodit

  • Naše společnosti
  • Aktuálně
  • Insights

Kontakty

  • Společnosti skupiny PPF
  • Podmínky používání
  • Ochrana osobních údajů
  • Mapa stránek
  • Cookies policy

2026 © PPF Group

Nejčastěji hledáte

Výroční zprávyInsightsVize a strategieTiskové zprávy

  • Insights

  • Biotech Market / Business Intelligence

  • September 2024 Biotechnology: Review of news from the most innovative therapeutic areas and the business development transactions

Slow IPO season may be coming to an end, as four biotechs completed IPO of $100+ million

SOTIO Biotech

15/10/2024 | 3 minuty čtení

Vytisknout
Kopírovat odkaz

A slow season for biotech IPOs may be coming to an end. In September, four biopharmas have completed NASDAQ listings in which each raised more than $100 million, including Bicara with $315 million IPO. Most recently, Upstream Bio filed for IPO seeking to raise $100 million.

Sdílet na sociálních sítích

Sdílet na sociálních sítích

Vytisknout

Kopírovat odkaz

Podobné články

SOTIO Biotech

15/10/2024

Rybrevant plus chemotherapy show 49 % ORR in metastatic colorectal cancer

SOTIO Biotech

15/10/2024

ArsenalBio announced $325 million financing to advance cell therapy programs

SOTIO Biotech

15/10/2024

Patritumab-Dx demonstrates a statistically significant Ph 3 PFS improvement in NSCLC

SOTIO Biotech

15/10/2024

ImmunityBio presented positive long-term OS data of Anktiva in NSCLC

SOTIO Biotech

15/10/2024

Legal Notice

Insights

Monthly market moves of selected competitors compared to NASDAQ Biotechnology Index (NBI)

09.2024_Monthly market moves

Area

Company

Ticker

Price range $

Δ  Price

MktCap $m

Δ MktCap $m

ADC

ADC Therapeutics

ADCT

2.70 – 3.33

9

%

304

24

Elevation Oncology

ELEV

0.58 – 0.73

-23

%

35

-11

Mersana Therapeutics

MRSN

1.35 – 2.19

20

%

216

35

Sutro Biopharma

STRO

3.32 – 4.61

-24

%

284

-91

IL15 / 2

ImmunityBio

IBRX

3.32 – 3.93

-6

%

2 591

-160

Mural Oncology

MURA

3.03 – 3.46

-6

%

53

-3

Nektar Therapeutics

NKTR

1.11 – 1.31

2

%

239

4

Werewolf Therapeutics

HOWL

2.00 – 2.40

-2

%

93

-2

CAR-T

Allogene Therapeutics

ALLO

2.41 – 2.96

6

%

586

36

Arcellx

ACLX

65.46 – 86.61

 21

%

4 489

794

Autolus Therapeutics

AUTL

3.45 – 4.44

-8

%

966

-80

Mustang Bio

MBIO

0.21 – 0.29

-16

%

9

-2

Other

Arcus Biosciences

RCUS

15.27 – 17.95

-11

%

1 398

 -167

Immutep

IMMP

2.21 – 2.64

-16

%

197

 -38

MacroGenics

MGNX

3.00 – 3.70

-6

%

206

 -14

ADC Therapeutics 

ADCT’s CEO Ameet Mallik participated and presented in two investor conferences in September: HC Wainwright Annual Global Investment Conference and Cantor Global Healthcare Conference. 

Elevation Oncology 

Elevation announced that FDA has granted Fast Track designation to EO-3021, a differentiated ADC, for the treatment of patients with advanced or metastatic gastric and gastroesophageal junction cancer expressing CLDN18.2 that has progressed on or after prior therapy. 

Mersana Therapeutics 

Short interest of Mersana increased by 21 % to 10,306,527 reported on September 15, compared to 8,487,549 on August 15. 

Sutro Biopharma 

Sutro announced updated data from the ongoing Phase 1b study of luveltamab tazevibulin (luvelta) in combination with bevacizumab for patients with epithelial ovarian cancer (EOC) in a poster presentation at the 2024 ESMO Congress. The 4.3 mg/kg of luvelta in combination with standard dose of bevacizumab (15 mg/kg) every 3 weeks resulted in a 56% ORR in patients with late-stage ovarian cancer and was selected to be the recommended phase 2 dose. 

ImmunityBio 

ImmunityBio announced positive results from its QUILT 3.055 trial demonstrating long-term extended survival of 14 months to as much as five years for patients with advanced NSCLC being treated with checkpoint inhibitors. An oral presentation of the data was presented at the World Congress on Lung Cancer in San Diego. The phase 2b study of Anktiva in combination with Keytruda or Opdivo in multiple tumor types including NSCLC who failed CPI showed long-term overall survival of 57 % and 34 % at 12 and 18 months respectively. 

Mural Oncology 

Mural hosted a virtual Investor Day and provided new clinical insight into the trial design, statistical assumptions, and progress of the company’s late-stage trials of nemvaleukin. Key data readouts for the company’s late-stage, potentially registrational trials of nemvaleukin are expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma. 

Nektar Therapeutic 

Nektar announced several presentations for rezpegaldesleukin at the 2024 European Academy of Dermatology and Venereology Congress. In addition to two trial-in-progress posters, new proteomic analyses were presented that showcases a unique serum proteomic profile in patients with atopic dermatitis. 

Werewolf Therapeutics 

Werewolf’s CEO Daniel J. Hicklin and CMO Randi Isaacs participated in a fireside chat at the HC Wainwright Global Healthcare Conference. 

Allogene Therapeutics 

Allogene presented preclinical data for its next-generation investigational AlloCAR T candidate for autoimmune indications, ALLO-329, at the American College of Rheumatology's annual meeting. ALLO-329 is a CD19/CD70 dual AlloCAR T product and is the first CAR T designed to both reduce or eliminate the need for lymphodepletion while also targeting CD19+ B-cells and CD70+ activated T-cells, both of which are likely to play a role in autoimmune diseases. 

Autolus Therapeutics 

Autolus announced the appointment of Matthias Will MD as Chief Development Officer, effective September 30, 2024. 

Arcellx 

Short interest of Arcellx decreased by 6 % to 4,752,245 reported on August 15, compared to 5,026,797 on July 15. 

Mustang Bio 

Short interest of Mustang decreased by 59 % to 656,396 reported on August 15, compared to 1,616,915 on July 15. 

Arcus Biosciences 

Arcus announced a clinical trial collaboration agreement with AstraZeneca to evaluate casdatifan, Arcus’s investigational HIF-2a inhibitor, in combination with volrustomig, AZ’s investigational PD-1/CTLA-4 bispecific antibody, in patients with RCC. 

Immutep 

Immutep announced positive efficacy and safety results from the TACTI-003 Phase 2b evaluating efti in combination with pembrolizumab as first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma patients, which led to a high durability of response of 17.5 months in patients with any PD-L1 expression. 

MacroGenics 

MacroGenics presented updated efficacy and safety results from the TAMARACK Phase 2 study of vobramitamab duocarmazine (vobra duo), an ADC targeting B7-H3, for patients with metastatic CRPC. Encouraging antitumor activity demonstrated with vobra duo as measured by 6-month landmark rPFS rate and ORR. Company expects to have mature median rPFS in early 2025.